Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00035503 | Multicenter Trial For Patients With Acute Crohn's Disease | PHASE2 | COMPLETED | - | — | — | Jan 31, 2002 | Jan 31, 2004 | Dec 8, 2021 | 11 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| etiprednol dicloacetate | DRUG | - |
* Must have active confirmed Crohn's disease with CDAI \> 220 and \< 400. * Otherwise healthy.